IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that due to the threat of COVID-19, the Company decided to delay enrollment in the second pivotal clinical trial for Zimura®.